Trial result ·
An open-label single-arm phase 1/2a study to evaluate the safety and exploratory efficacy of a VM202 in patients with Charcot-Marie-Tooth disease 1A.
Written based on 1 research study on PubMed, searched on 13 Nov 2026.
What was studied
This study tested a gene therapy called VM202. It was given to people with Charcot-Marie-Tooth disease type 1A, or CMT1A. VM202 carries DNA for a human growth factor. It was an early trial, phase 1/2a, with no comparison group. Everyone knew they were getting the drug. 12 people joined and got shots into the muscles of both legs. Shots came at the start and on days 14, 90, and 104. The team then followed people for 270 days.
What they found
The main goal was to check safety. All people handled VM202 well. No serious harms linked to the drug were seen. Several nerve scores went down between the start and day 270. For example, the CMTNSv2 score fell by 2.17 points on average. The CMTES score fell by 2.50 points on average. A score of daily function, called FDS, also went down. A leg score called ONLS did not change in a clear way. The 10-meter walk test also showed no clear change.
What it means for patients
The authors say VM202 shots seem safe and well handled in CMT1A. They also saw early, exploratory signs of an effect. They say these signs must be checked in a phase 2b trial. In that kind of trial, people are put in groups by chance.
Why it is not certain yet
Only 12 people took part. There was no comparison group, so changes may have other causes. People and doctors knew who got the drug. Follow-up lasted 270 days. Some tests, like the walk test, showed no clear change. The trial was registered after it had started.
Source
An open-label single-arm phase 1/2a study to evaluate the safety and exploratory efficacy of a VM202 in patients with Charcot-Marie-Tooth disease 1A.
PubMed · PMID 41787447We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Charcot-Marie-Tooth disease publications